Catalyst Pharmaceutical (CPRX)

• Market cap: $2.58B
• 1 day: 0.09%
• 5 days: -2.08%
• 1 month: 2.03%
• 3 months: 5.46%
• 6 months: 40.48%
• Year to date: 26.36%
• 1 year: 26.14%
• 5 years: 440.50%
• 10 years: 645.52%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Employees: 167

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

164% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 25

25% more capital invested

Capital invested by funds: $1.52B [Q2] → $1.89B (+$375M) [Q3]

15% more funds holding

Funds holding: 270 [Q2] → 311 (+41) [Q3]

2.75% less ownership

Funds ownership: 83.0% [Q2] → 80.26% (-2.75%) [Q3]

10% less repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 106

25% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]

61% less call options, than puts

Call options by funds: $610K | Put options by funds: $1.58M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $30 39% upside
• Avg. target: $34 56% upside
• High target: $36 67% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Stephens & Co. Sudan Loganathan 21% 1-year accuracy 4 / 19 met price target	62% upside $35	Overweight Initiated	18 Nov 2024
Truist Securities Joon Lee 46% 1-year accuracy 17 / 37 met price target	67% upside $36	Buy Maintained	11 Nov 2024
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 102 / 328 met price target	39% upside $30	Buy Reiterated	8 Nov 2024